BIOMAT Database Logo BIOMAT Database Logo

Adjuvant radiotherapy in Ta, T1 and T2 bladder tumors after transurethral resection--a retrospective study. 1984

H Rubben, and W Lutzeyer, and K D Ebbinghaus, and H H Dahm

UI MeSH Term Description Entries
D008297 Male Males
D011882 Radiotherapy, High-Energy Radiotherapy using high-energy (megavolt or higher) ionizing radiation. Types of radiation include gamma rays, produced by a radioisotope within a teletherapy unit; x-rays, electrons, protons, alpha particles (helium ions) and heavy charged ions, produced by particle acceleration; and neutrons and pi-mesons (pions), produced as secondary particles following bombardment of a target with a primary particle. Megavolt Radiotherapy,High-Energy Radiotherapy,Radiotherapy, Megavolt,High Energy Radiotherapy,Radiotherapy, High Energy
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

H Rubben, and W Lutzeyer, and K D Ebbinghaus, and H H Dahm
[Second resection in patients with Ta-T1 bladder tumors].
September 2001, Actas urologicas espanolas,
H Rubben, and W Lutzeyer, and K D Ebbinghaus, and H H Dahm
[Transurethral surgical treatment of invasive bladder tumors (T1 and T2)].
November 1987, Ugeskrift for laeger,
H Rubben, and W Lutzeyer, and K D Ebbinghaus, and H H Dahm
Adjuvant systemic chemotherapy after complete transurethral resection of superficially invasive bladder carcinoma (T1 G3-4 and T2 G2-4).
January 1990, Urologia internationalis,
H Rubben, and W Lutzeyer, and K D Ebbinghaus, and H H Dahm
Second transurethral resection and adjuvant radiotherapy in conservative treatment of pT2N0M0 bladder tumors.
May 2003, European urology,
H Rubben, and W Lutzeyer, and K D Ebbinghaus, and H H Dahm
Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer.
April 2012, Current urology reports,
H Rubben, and W Lutzeyer, and K D Ebbinghaus, and H H Dahm
Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection.
January 2024, The French journal of urology,
H Rubben, and W Lutzeyer, and K D Ebbinghaus, and H H Dahm
A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.
August 2001, BJU international,
H Rubben, and W Lutzeyer, and K D Ebbinghaus, and H H Dahm
Residual tumour in the marginal resection after a complete transurethral resection is associated with local recurrence in Ta/T1 urinary bladder cancer.
October 2012, Scandinavian journal of urology and nephrology,
H Rubben, and W Lutzeyer, and K D Ebbinghaus, and H H Dahm
Repeat transurethral resection lowers recurrence rates in T1 bladder tumors, even after intravesical mitomycin C.
November 2006, Nature clinical practice. Urology,
H Rubben, and W Lutzeyer, and K D Ebbinghaus, and H H Dahm
[Conservative treatment with transurethral resection of stage T2 cancer of the bladder: retrospective study].
January 1989, Actas urologicas espanolas,
Copied contents to your clipboard!